AiVita Biomedical is advancing commercial and clinical-stage programs utilizing curative and regenerative medicines. Built upon expertise in stem cell growth and directed, high-purity differentiation, AiVita Biomedical has engineered safe, efficient and economical manufacturing systems to support the development and commercialization of curative and regenerative medicines.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/13/16 | $2,000,000 | Series A | ||
| 01/05/21 | $25,000,000 | Series B-2 |
